Intercytex appoints new Chief Financial Officer

22nd August 2008

Intercytex Group plc (LSE: ICX) (“Intercytex” or “the Company”), the leading developer of regenerative medicine products to restore skin and hair, is pleased to announce the appointment of Max Herrmann (42) as the Company’s new Chief Financial Officer with effect from 19 September 2008.

Max joins Intercytex from Fusion IP plc, the university IP commercialisation company, where he has held an independent consulting role for the past 12 months. Prior to this, Max spent over 10 years as a sell-side equity analyst, most recently as Managing Director and Head of European Pharmaceutical and Biotechnology Research at ING Equity Markets, responsible for a highly rated team of analysts focused on the pharmaceutical, biotechnology and healthcare sectors.

Prior to his successful career in the City, Max worked in the US for Onyx Pharmaceuticals Inc. as Financial Controller. In this role he was integrally involved in the company’s successful initial public offering on NASDAQ in May 1996.Max qualified as a Chartered Accountant with Arthur Andersen in 1993. He holds a degree in Microbiology from the University of Kent.

Nick Higgins, Chief Executive Officer of Intercytex, said:

“We are delighted to welcome Max to the Intercytex team. His strong financial background and experience in the City combined with his deep scientific understanding of our sector brings a wealth of knowledge and expertise to Intercytex, and I am certain that he will make a major contribution to the Company’s future growth and development.”

There are no other disclosures required under Schedule Two paragraph (g) of the AIM Rules for Companies.